Brief: Transgene And BioInvent Announce Positive Progress For BT-001

BioInvent International AB

27/06/2022 07:05

June 27 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE AND BIOINVENT ANNOUNCE POSITIVE PROGRESS FOR
BT-001
    * POSITIVE PROGRESS AND SAFETY DATA OF ONGOING PHASE I/IIA
TRIAL
EVALUATING BT-001 IN PATIENTS WITH SOLID TUMORS, INCLUDING
MELANOMA
    * INITIAL DATA IN PHASE I PART A SHOWED THAT BT-001 ALONE IS
WELL
TOLERATED, WITH FIRST SIGNS OF ANTI-TUMOR ACTIVITY IN
HARD-TO-TREAT POPULATION AND CONFIRMED MECHANISM OF ACTION OF
BT-001 AS A SINGLE AGENT
    * FIRST TWO DOSE LEVELS HAVE BEEN SUCCESSFULLY COMPLETED,
WITH 12
PATIENTS DOSED TO DATE
    * PHASE I PART B IS PLANNED TO START IN H2 2022

Source text for Eikon:  ID:nBw2xWykMa 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))